Status: Recruiting
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies.
Participants needed: 10
Trial details
Phase: Early Phase 1Age: 3-70Biological sex: AllType: InterventionalSponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Updated: May 16, 2025Locations: 1
Eligibility criteria
Patients aged between 3~70 (including cut-off values), regardless of gender and... [+8]
Those with graft-versus-host disease (GVHD) or requiring long-term systemic immu... [+10]